1h Free Analyst Time
The endocrinology drugs market is forecasted to grow by USD 40.14 billion during 2024-2029, accelerating at a CAGR of 7.6% during the forecast period. The report on the endocrinology drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in incidence of endocrine disorders, promising pipeline for endocrinology, and research in novel dosage formulations and drug delivery systems.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The endocrinology drugs market is segmented as below:
By Therapy Area
- Diabetes drugs
- hGH
- Thyroid hormone disorders
- Others
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the endocrinology drugs market covers the following areas:
- Endocrinology Drugs Market sizing
- Endocrinology Drugs Market forecast
- Endocrinology Drugs Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Therapy Area
9 Market Segmentation by Distribution Channel
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global endocrinology drugs market: Abbott Laboratories, Acerus Pharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and VeroScience LLC.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is association between obesity and endocrine disorders."
According to the report, one of the major drivers for this market is the increase in incidence of endocrine disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Acerus Pharmaceuticals Corp.
- Ascendis Pharma AS
- Bayer AG
- Beta Cell NV
- Biocon Ltd.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Hanmi Pharm Co. Ltd.
- Ipsen Pharma
- Merck and Co. Inc.
- Novartis AG
- Novo Nordisk AS
- Oramed Pharmaceuticals Inc.
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- VeroScience LLC
